Phase 4 bloodstream infection Clinical Trials
8 recruitingPhase 4
What is a Phase 4 trial?
Phase 4 trials, also called post-marketing studies, are conducted after a treatment has been approved and is available to the public. They monitor long-term effectiveness and safety in a broader population.
Showing 1–8 of 8 trials
Recruiting
Phase 4
Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)Staphylococcus Aureus BacteraemiaStaphylococcal Bacteraemia+1 more
Region Skane420 enrolled1 locationNCT06726395
Recruiting
Phase 4
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
Staphylococcus Aureus BacteremiaStaphylococcus Aureus EndocarditisStaphylococcus Aureus Septicemia+3 more
McGill University Health Centre/Research Institute of the McGill University Health Centre300 enrolled1 locationNCT06650501
Recruiting
Phase 4
Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia
Staphylococcus Aureus EndocarditisStaphylococcus Aureus SepticemiaStaphylococcus Aureus Bloodstream Infection
Todd C. Lee MD MPH FIDSA300 enrolled1 locationNCT06650488
Recruiting
Phase 4
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Staphylococcus Aureus BacteremiaStaphylococcus Aureus EndocarditisStaphylococcus Aureus Septicemia+2 more
Todd C. Lee MD MPH FIDSA300 enrolled14 locationsNCT06637332
Recruiting
Phase 4
Optimising TREATment for Severe Gram-Negative Bacterial Infections
bloodstream infectionCarbapenem Resistant Bacterial InfectionMultidrug Resistance+2 more
National University of Singapore600 enrolled41 locationsNCT07004049
Completed
Phase 4
Antimicrobial disc (AMD) infection prevention in central venous catheters
Central-line associated bloodstream infection
Griffith University66 enrolled1 locationACTRN12619000918123
Completed
Phase 4
Pilot randomised controlled trial of meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections.
Participants who have had a bloodstream infection with a specific gram negative bacteria, as defined by at least one positive blood culture, where the isolate is confirmed to be a likely AmpC-producer by resistance to Ampicillin, Amoxicillin/clavulanate and 1st generation cephalosporins (e.g. cephazolin). The isolate should also remain susceptible to piperacillin/tazobactam and meropenem.
The University of Queensland Centre for Clinical Research100 enrolled6 locationsACTRN12614001211651
Completed
Phase 4
Pilot Randomized Control Trial of Meropenem vs. Piperacillin-Tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia Coli and Klebsiella spp.
Participants who have had an identified Escherichia Coli or Klebsiella spp. bloodstream infection that is found non-susceptible to Ceftriaxone.
Australasian Society of Infectious Diseases Clinical Research Network100 enrolled11 locationsACTRN12613000532707